Terray Therapeutics rakes in $120M for AI-powered small-molecule drug development Terray Therapeutics, a biotechnology company using artificial intelligence to accelerate the development of small-molecule drugs, said today it has raised $120 million in a Series B fundraise to enhance its AI platform. New investor Bedford Ridge Capital and existing investor NVentures, Nvidia Corp.’s venture capital arm, led the funding round. The round also attracted investments from Maverick Capital, Goldcrest C...